


A Cochlea-Sparing Strategy for Non-Invasive Control of Intracranial Schwannomas via Peripheral Irradiation and Anti-PD-1 Therapy Enhanced by STING Activation

Authors

Zhenzhen Yin^{1,a}, Simeng Lu^{1,a}, Limeng Wu¹, Yao Sun^{1,2}, Day Caven Blake¹, Jie Chen¹, Lukas D. Landegger³, William Ho¹, Bingyu Xiu¹, Adam P. Jones¹, Alona Muzikansky⁴, Helen A. Shih⁵, Konstantina M. Stankovic³, Scott R. Plotkin⁶, and Lei Xu^{1,*}

Supplementary Figures






Figure S2. Combined radiotherapy and αPD1 treatment achieve enhanced efficacy in *Nf2*^{-/-} model.

(A) Representative immunofluorescent staining images of CD3 in *Nf2*^{-/-} tumors.

(B) Representative images of TUNEL staining for apoptotic cells

(C) Representative images of PCNA staining for proliferating tumor cells.

Image quantification and flow cytometry data are presented as mean ± s.d., and analyzed using Student's t-test and the Mann-Whitney test.

Table S1. Antibody panels.

Flow cytometry antibodies			
Surface Markers	Clone	Fluorophore	Catalog Number
CD11b	M1/70	APC-Cy7	BioLegend 101212
CD11c	N418	PE/Cy7	BioLegend 117324
CD206	C068C2	PE	BioLegend 141706
CD3	17A2	PE-cy7	BioLegend 100219
CD4	GK1.5	FITC	BioLegend 100405
CD45	30-F11	PerCP	BioLegend 103130
CD8	53-6.7	APC-cy7	BioLegend 100713
CD86	GL1	PE	BioLegend 105008
F4/80	BM8	PE-Cy7	BioLegend 123114
Foxp3	MF-14	PE	BioLegend 126403
Gr1	RB6-8C5	PE	BioLegend 108408
Granzyme B	QA16A02	APC	BioLegend 372204
IFN- γ	XMG1.2	PE/Dazzle594	BioLegend 505846
MHCII	M5/114.15.2	APC	BioLegend 107614
NK1.1	S17016D	APC	BioLegend 156505
TNF- α	MP6-XT22	PE	BioLegend 506306
Treatment antibodies			
Target	Clone	Company	Catalog Number
Anti-CD4	GK1.5	BioXCell	BE0003-1
Anti-CD8	2.43	BioXCell	BE0061